[THE CORRECTION OF THE LOCAL IMMUNE RESPONSE AT THE PATIENTS WITH HELICOBACTER PYLORI INFECTION].
BACKGROUND
Helicobacter pylori infection is due to the high prevalence in population attracts the clinical interest of researchers in the whole World. It is well known that this microorganism not only resides in the mucosa of the gastrointestinal tract, but is also defined in the periodontal pocket of the oral cavity. THE AIM OF INVESTIGATION: to evaluate Helicobacter pylori diagnostics in the mouth and prove a method of relief of the inflammatory process by applying immunomodulator Imudon. RESULTS. On the basis of obtained results it was found that the inclusion of topical immunomodulator Imudon in the complex therapy of Helicobacter pylori-associated diseases leads to reduction of inflammatory potential through the decrease of the TNFα, IL-6 activity in saliva and to increase the protective properties of saliva as a result of increased levels of mucin, significantly reduces the frequency of relapses in the one year after therapy.


CONCLUSIONS
It is practically important to determine the effectiveness of eradication therapy by the study of the contents of the tooth-gingival pocket for the detection of genetic material of Helicobacter pylori, as well as to include in the complex therapy of Helicobacter pylori-associated diseases of the immune modulator Imudon.
A S
AS
Sarsenbaeva
A V
AV
Smolyagina
V A
VA
Akhmedov
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D018928:Immunity, Mucosal / Q000187:drug effects*; D015850:Interleukin-6 / Q000276:immunology / Q000378:metabolism; D008297:Male; D012463:Saliva / Q000276:immunology / Q000378:metabolism*; D013849:Thimerosal / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D000946:Antigens, Fungal; D004338:Drug Combinations; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; C011874:imudon; D013849:Thimerosal